Anupam Rasayan India Limited has completed its open offer for Bliss GVS Pharma Limited, acquiring a nominal stake from public shareholders.

Anupam Rasayan India acquired 1,669 fully paid-up equity shares of the target company at an offer price of ₹299.00 per share. The total consideration paid for these shares amounted to ₹4,99,031. This acquisition represents 0.00% of the expanded voting share capital of Bliss GVS Pharma Limited.

Offer Details and Outcomes

The open offer, managed by SBI Capital Markets Limited, was open for tendering between July 28, 2026, and August 10, 2026. Consideration for the validly tendered shares was paid on August 24, 2026. The offer initially sought to acquire up to 2,77,26,848 shares, representing 26.00% of the expanded voting share capital. However, the actual number of shares tendered and accepted was significantly lower than the maximum proposed.

Underlying Transaction Status

The open offer was initiated pursuant to an agreement for the acquisition of a minimum of 4,58,03,024 equity shares (Base Shares), representing 43.11% of the equity share capital of Bliss GVS Pharma Limited. As per the post-offer advertisement, this underlying transaction under the Share Purchase Agreement (SPA) remains unconsummated. The acquirer holds an option to acquire additional residual shares held by sellers Narsimha Shiroor Kamath, Gautam Rasiklal Ashra, and Ajun Gautam Ashra at the same price of ₹299.00 per share.

All 1,669 shares acquired through the open offer have been credited to the demat account of Anupam Rasayan India Limited. The company intends to transfer these shares to its person acting in concert (PAC), Mates Visa Consultancy Private Limited, in due course. The public shareholders' holding remained effectively unchanged at 52.18% post-offer.

Anupam Rasayan India Limited reported a 36% year-on-year increase in consolidated total income to ₹6,675 crore for the quarter ended June 30, 2026. Consolidated profit after tax (PAT) rose 6% to ₹512 crore, while EBITDA grew 35% to ₹1,749 crore, maintaining margins at 26%. The company filed its unaudited financial results with the Bombay Stock Exchange on August 15, 2026, pursuant to Regulation 47 of the SEBI (LODR) Regulations, 2015.

Financial Performance and Segment Contributions

On a standalone basis, revenue grew 4% year-on-year to ₹3,349 crore (including other income), compared to ₹3,205 crore in Q1FY26. Standalone EBITDA expanded 17% to ₹1,155 crore, with margins improving to 34% from 31%. Standalone PAT increased 8% to ₹320 crore.

During the earnings call held on August 14, 2026, management provided deeper insights into segment performance. Jayhawk Fine Chemicals, acquired recently, contributed approximately 20-22% of the consolidated revenue this quarter. Jayhawk’s revenue was around ₹145 crore, with EBITDA margins reported at 19-20% (approximately ₹30 crore) and PAT at roughly ₹9 crore. The lower PAT relative to EBITDA was attributed to higher depreciation expenses due to the increased asset base and differences in depreciation policies post-acquisition.

Consolidated cash profit stood at ₹64 crore, up from ₹56 crore in the prior year. Working capital remained largely stable, with management expecting further improvements in FY27 due to tighter inventory and receivable management.

Strategic Developments and Acquisitions

A key technological milestone during the quarter was the commercialization of Ethyl Trifluoroacetate (ETFA) using flow chemistry. Anupam Rasayan is the first company globally to commercialize ETFA through this technology, which improves safety, product quality, and scalability. The company estimates the market size for these molecules at approximately $0.5 billion.

The proposed acquisition of Bliss GVS Pharma continues to progress as planned. Management confirmed that SEBI approval has been received, and the open offer period concluded on August 10, 2026. The transaction is expected to be fully consummated in the first half of September 2026. Post-acquisition, Anupam intends to leverage Bliss GVS’s regulated manufacturing capabilities to build an integrated pharmaceutical platform. The funding structure involves a debt of around ₹300 crore, with the balance raised through equity-linked instruments.

Additionally, the company signed a Letter of Intent (LoI) with BASQUEVOLT for the potential long-term supply of a specialty chemical product. This opportunity represents approximately $300 million spread over 10 years, with commercialization expected to begin in FY27. Cumulative signed LoIs and contracts now represent roughly ₹18,000 crore of potential business over their respective tenures.

Capital Expenditure and Outlook

Management indicated that the major capital expenditure cycle undertaken over the last few years has been completed. All major planned projects are now operational. Consequently, no significant capex is foreseen for the existing Anupam platform in the near term. Future capex is expected to be selective, estimated at ₹70-80 crore annually, primarily for repair, maintenance, or repurposing. Jayhawk remains unlevered and well-capitalized, requiring no additional funding from Anupam for its capex needs.

Looking ahead, the company expects organic revenue growth of 25% plus or minus a couple of percentage points for FY27. With the addition of Jayhawk’s full-year contribution, total growth could be higher. The polymer business is projected to contribute 20-25% on a standalone basis and 30-35% on a consolidated basis. Management guided that standalone EBITDA margins should remain in the range of 24-26%, while consolidated margins are expected to be between 22-24% due to the diversified nature of the portfolio.

What the Numbers Show

The divergence between consolidated revenue growth (36%) and PAT growth (6%) highlights the impact of integration costs and depreciation from recent acquisitions, particularly Jayhawk. While top-line momentum is strong, driven by new product launches like ETFA and the inclusion of Jayhawk, bottom-line expansion has been muted by higher fixed charges. However, the stability of EBITDA margins at 26% despite a shifting mix towards performance materials suggests effective operational leverage. The upcoming closure of the Bliss GVS deal will further diversify revenue streams, though it may temporarily pressure cash flows due to the debt component of the acquisition funding.

Board Appointments and Governance

During its meeting on August 14, 2026, the Board of Directors approved the unaudited financial results. The board also appointed Mr. Ravi Desai as Chief Operating Officer, effective immediately. The interim results were reviewed by Natvarlal Vepari & Co., Chartered Accountants, Surat, in accordance with Standard on Review Engagements (SRE) 2410.